SurVaxM

AssetVaccine

Vaccine targeting survivin (BIRC5) to stimulate an anti-tumor immune response.

Stage
Phase 2
Modality
Vaccine
Target
Apoptosis
Indications
2
Trials
0
Developers
1

Indications

2
  • Targets and what it contains2
  • Owner and partners2
  • Evidence for its targets1
  • Signals1

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Updated 7 Oct 2026 · 1 source

Assets